The first anti-VEGF drug approved for clinical application was bevacizumab (Avastin®, Roche), a humanized monoclonal antibody directed against all VEGF-A isoforms, which has shown clinical benefit and efficacy in several types of malignancies including metastatic colorectal cancer (mCRC). This evidence concerns the gene VEGFA and metastatic colorectal cancer.